Vorinostat increases carboplatin and pac
✍
Taofeek K. Owonikoko; Suresh S. Ramalingam; Beatriz Kanterewicz; Trent E. Balius
📂
Article
📅
2010
🏛
John Wiley and Sons
🌐
French
⚖ 533 KB
## Abstract We observed a 53% response rate in non‐small cell lung cancer (NSCLC) patients treated with vorinostat plus paclitaxel/carboplatin in a Phase I trial. Studies were undertaken to investigate the mechanism (s) underlying this activity. Growth inhibition was assessed in NSCLC cells by MTT